Description
PHT-427 is an inhibitor of PDK1 and Akt that exhibits anticancer chemotherapeutic activity, inhibiting tumor growth in animal models of breast cancer and non-small cell lung cancer (NSCLC).
PHT-427 is an inhibitor of PDK1 and Akt that exhibits anticancer chemotherapeutic activity, inhibiting tumor growth in animal models of breast cancer and non-small cell lung cancer (NSCLC).
| Cas No. | 1191951-57-1 |
|---|---|
| Purity | ≥98% |
| Formula | C20H31N3O2S2 |
| Formula Wt. | 409.61 |
| IUPAC Name | 4-dodecyl-N-(1,3,4-thiadiazol-2-yl)benzenesulfonamide |
| Synonym | PHT427 |
| Appearance | White Crystal Powder |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| Info Sheet | P3076 Info Sheet PDF |
|---|---|
| Brochures | PI3K-Akt-mTORC Pathway Booklet |
Meuillet EJ, Zuohe S, Lemos R, et al. Molecular pharmacology and antitumor activity of PHT-427, a novel Akt/phosphatidylinositide-dependent protein kinase 1 pleckstrin homology domain inhibitor. Mol Cancer Ther. 2010 Mar;9(3):706-17. PMID: 20197390.